



## Message from PHE Screening

|   |   |
|---|---|
| <b>Subject</b>                                    | <b>Advice for women following Covid-19 vaccination</b>  |
| <b>Message source</b>                             | PHE Breast Screening Team   |
| <b>Message recipients</b>                         | <b>See checklist below</b>  |
| <b>Importance</b>                                 | <input type="checkbox"/> Normal <input checked="" type="checkbox"/> High  |
| <b>Message</b>                                    | <p>A recent <a href="#">BMJ article</a>, reported that advice in the US is that breast screening appointments should be scheduled to take place before women receive a first dose of Covid-19 vaccine or 4 to 6 weeks after the second dose where possible. This is due to the potential reaction of enlarged lymph nodes (lymphadenopathy) on the side of the vaccination, which could cause unnecessary concern. This has also picked up by the UK press. For the vaccines approved for use in the UK, the frequency from the trials is estimated to be less than 1%.</p> <p>Within England, breast screening service personnel are advised to be aware of the potential for enlarged nodes following a Covid-19 vaccination. However, the advice regarding the scheduling of mammograms has not altered. There is currently no requirement for women to be advised to wait for a period of time following a Covid-19 vaccination before attending a screening appointment.</p> <p>As per usual practice, women with noted lymphadenopathy at screening must always be recalled for assessment even if they report recent vaccination. This is to ensure that no other pathology exists. It may be useful for clinicians at an assessment appointment to determine the date of a Covid-19 vaccination and the arm in which this was given, where enlarged lymph nodes are being investigated.</p> <p>We will continue to monitor the evidence in this emerging area and take advice from relevant experts. Updates will be issued as necessary.</p> |
| <b>Action required</b>                            | Services to ensure that this cascade message is shared with all relevant service personnel.   |
| <b>Contact for queries</b>                        | <a href="mailto:PHE.screeninghelpdesk@nhs.net">PHE.screeninghelpdesk@nhs.net</a>  |
| <b>Message ref. number<br/>(IEPP to complete)</b> |   |

## Distribution checklist: message to go to all checked groups below.

### IEPP to distribute to:

NHSEI national team (for all emails to SILs, SIMs and NHS screening providers)

- |  |  |
|--|--|
| <input type="checkbox"/> PHE Screening all staff           | <input type="checkbox"/> Bowel screening hub managers  |
| <input checked="" type="checkbox"/> PHE screening helpdesk | <input type="checkbox"/> Bowel screening hub directors |
|  | <input type="checkbox"/> Lead midwives for education   |

Sender defined group (tick this box, describe group below, and send contact list with this form)

Description of the group: [YPA - BSP Cascade Distribution List](#)

### ANNB – Newborn Hearing Screening Programme to distribute to:

- |  |  |
|--|--|
| <input type="checkbox"/> NHSP local managers | <input type="checkbox"/> NHSP screeners        |
| <input type="checkbox"/> NHSP team leaders   | <input type="checkbox"/> NHSP senior screeners |
| <input type="checkbox"/> NHSP audiologists   | <input type="checkbox"/> NHSP learning mentors |

### Regional SQAS to distribute (using Bcc) to:

Note: also Bcc message to relevant programme QA teams

#### SQAS

- |   |   |
|---|---|
| <input checked="" type="checkbox"/> Relevant heads and regional heads of QA | <input checked="" type="checkbox"/> Screening and immunisation leads    |
|   | <input checked="" type="checkbox"/> Screening and immunisation managers |

#### Abdominal aortic aneurysm (AAA)

- |   |   |
|---|---|
| <input type="checkbox"/> Clinical directors | <input type="checkbox"/> Programme managers |
|---|---|

#### Diabetic eye screening (DES)

- |   |   |
|---|---|
| <input type="checkbox"/> Programme managers | <input type="checkbox"/> Clinical leads |
|---|---|

#### ANNB- Antenatal & newborn

- |  |  |
|--|--|
| <input type="checkbox"/> Heads of midwifery      | <input type="checkbox"/> Child health record departments |
| <input type="checkbox"/> Screening co-ordinators |  |

#### ANNB - Fetal anomaly screening (FASP)

- |   |   |
|---|---|
| <input type="checkbox"/> FASP screening laboratories    | <input type="checkbox"/> FASP genomics laboratories |
| <input type="checkbox"/> Screening support sonographers |   |

#### ANNB - Infectious diseases in pregnancy (IDPS)

- |   |   |
|---|---|
| <input type="checkbox"/> IDPS screening laboratories (microbiology, virology) | <input type="checkbox"/> Specialist nurses/midwives |
| <input type="checkbox"/> IDPS reference laboratories                          | <input type="checkbox"/> Hepatologists              |

#### ANNB - Newborn screening (NBS)

- NBS screening laboratories

#### ANNB - Newborn & infant physical examination (NIPE)

- |  |   |
|--|---|
| <input type="checkbox"/> Provider NIPE programme leads | <input type="checkbox"/> Provider NIPE Clinical Leads |
|--|---|

#### ANNB - Sickle cell & thalassemia (SCT)

- |  |   |
|--|---|
| <input type="checkbox"/> SCT screening laboratories                            | <input type="checkbox"/> SCT specialist haemoglobinopathy centres (nursing) |
| <input type="checkbox"/> SCT DNA laboratories                                  | <input type="checkbox"/> SCT specialist haemoglobinopathy centres (medical) |
| <input type="checkbox"/> Haemoglobinopathy nurses/counsellors PND laboratories |   |

#### Bowel cancer screening

- |  |   |
|--|---|
| <input type="checkbox"/> Programme managers                      | <input type="checkbox"/> Lead radiology |
| <input type="checkbox"/> Clinical directors                      | <input type="checkbox"/> Lead pathology |
| <input type="checkbox"/> Lead specialist screening practitioners |   |

### Breast screening

- |  |   |
|--|---|
| <input checked="" type="checkbox"/> Programme managers | <input checked="" type="checkbox"/> Screening directors                 |
| <input checked="" type="checkbox"/> Breast care nurses | <input type="checkbox"/> Radiographers                                  |
| <input checked="" type="checkbox"/> Breast surgeons    | <input checked="" type="checkbox"/> Superintendent radiographers        |
| <input type="checkbox"/> Medical directors             | <input checked="" type="checkbox"/> Radiologists                        |
| <input checked="" type="checkbox"/> Office managers    | <input checked="" type="checkbox"/> Breast consultant practitioners     |
| <input type="checkbox"/> PACS managers                 | <input checked="" type="checkbox"/> Breast physicians/clinicians        |
| <input type="checkbox"/> Pathologists                  | <input checked="" type="checkbox"/> Advanced practitioner image readers |
|  | <input type="checkbox"/> Medical physics providers                      |

### Cervical screening

- |   |  |
|---|--|
| <input type="checkbox"/> Lead cytopathologists    | <input type="checkbox"/> Cervical screening provider leads                                   |
| <input type="checkbox"/> Lead histopathologists   | <input type="checkbox"/> Cytology lab managers   |
| <input type="checkbox"/> Colposcopy co-ordinators | <input type="checkbox"/> Cervical Screening Administration Service (CSAS) screening managers |
| <input type="checkbox"/> Lead colposcopists       |  |
| <input type="checkbox"/> Lead colposcopy nurses   |  |

Version: February 2020